Register for our free email digests:
Merck & Co., Inc.
http://www.merck.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck & Co., Inc.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Roche Hit By Surprising Tecentriq Miss In TNBC
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abmaxis
- Acacia Biosciences
- Afferent Pharmaceuticals
- ArQule, Inc.
- Avecia Biologics Limited
- Banyu Pharmaceutical Co., Ltd.
- Calporta Therapeutics
- cCAM Biotherapeutics Ltd.
- Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.)
- Idenix Pharmaceuticals, Inc.
- Immune Design Corporation
- Inspire Pharmaceuticals, Inc.
- IOmet Pharma
- iOnctura SA
- Integrated Therapeutics Group
- Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
- MSD K.K. (Japan)
- Nobilon International BV
- Novacardia
- OncoEthix SA
- Organon BioSciences
- Peloton Therapeutics, Inc.
- Rigontec GmbH
- Schering-Plough Corporation
- SmartCells, Inc.
- Tilos Therapeutics, Inc.
- Vallee S.A.
- Viralytics Limited (ASX:VLA)
- Themis Biosciences GmbH